Namaxir (Methotrexate)

Methotrexate, the active ingredient in Namaxir, is an Antimetabolite presented as a solution for Subcutaneous use. It is employed to manage rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia and Crohn's disease in appropriate patients.

GNH USA supplies Namaxir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate is used across several disease categories where immune modulation or anti‑proliferative effects are required.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with malignant cell replication. - Crohn's disease: alleviates intestinal inflammation and promotes remission.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: generalized tiredness. - Oral ulceration: sores in the mouth. - Elevated liver enzymes: transient hepatic enzyme rise. - Cytopenias: mild reduction in blood cell counts.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring monitoring. - Pulmonary fibrosis: progressive lung scarring. - Severe infection: opportunistic infections due to immunosuppression. - Bone marrow failure: aplastic anemia. - Renal toxicity: impaired kidney function.

Methotrexate requires careful monitoring and specific safety measures.

- Pregnancy contraindication: avoid use in pregnancy (Category X). - Liver monitoring: perform regular liver function tests. - Hematologic monitoring: check complete blood counts frequently. - Renal function: assess kidney function before and during therapy. - Concomitant drugs: avoid live vaccines and limit NSAID use. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methotrexate interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - NSAIDs: increase risk of toxicity. - Penicillins: may enhance myelosuppression. - Sulfonamides: potentiate hematologic effects. - Live vaccines: risk of severe infection. - Alcohol: exacerbates liver injury.

Moderate Interactions (Monitor Closely): - Warfarin: may increase anticoagulant effect. - Proton pump inhibitors: can affect absorption. - Trimethoprim‑sulfamethoxazole: may increase myelosuppression. - Azathioprine: additive immunosuppression. - Vitamin supplements containing folic acid: may reduce efficacy.